In vitro antibacterial activities and minimum inhibitory concentration of the synthesized compounds against MDR clinical isolates.
| Comp. no. | K. pneumoniae | MRSA1 | ||
|---|---|---|---|---|
| Diameter of zone inhibition in mm (15 μg mL−1) | MIC (μg mL−1) | Diameter of zone inhibition in mm (15 μg mL−1) | MIC (μg mL−1) | |
| 2b | 25 | 50 | 8 | — |
| 2c | 8 | — | 26 | 25 |
| 2d | 6 | — | 28 | 25 |
| 3a | 24 | 50 | 10 | — |
| 3b | 27 | 50 | 12 | — |
| 3c | 9 | — | 24 | 12.5 |
| 3d | 6 | — | 6 | — |
| 5 | 23 | 50 | 8 | — |
| 6 | 22 | 50 | 10 | — |
| 7 | 20 | 50 | 8 | — |
| 8a | 28 | 12.5 | 6 | — |
| 8b | 27 | 25 | 8 | — |
| 8c | 12 | — | 28 | 50 |
| 8d | 10 | — | 25 | 50 |
| 9a | 27 | 25 | 5 | — |
| 9b | 29 | 25 | 7 | — |
| 9c | 13 | — | 27 | 25 |
| 9d | 11 | — | 29 | 12.5 |
| Cephalothin | — | — | — | — |
| Chloramphenicol | — | — | — | — |